BIOCON2024-10-012024-12-31 BIOCON2024-10-012024-12-31 BIOCON2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member BIOCON2024-10-012024-12-31in-bse-fin:OneOperatingExpenses02Member BIOCON2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member BIOCON2024-10-012024-12-31in-bse-fin:FourOperatingExpenses02Member BIOCON2024-12-31 BIOCON2024-10-012024-12-31in-bse-fin:OneReportableSegmentRevenue01Member BIOCON2024-10-012024-12-31in-bse-fin:OneReportableSegmentRevenue02Member BIOCON2024-10-012024-12-31in-bse-fin:OneReportableSegmentRevenue03Member BIOCON2024-10-012024-12-31in-bse-fin:OneReportableSegmentRevenue04Member BIOCON2024-10-012024-12-31in-bse-fin:FourReportableSegmentRevenue01Member BIOCON2024-10-012024-12-31in-bse-fin:FourReportableSegmentRevenue02Member BIOCON2024-10-012024-12-31in-bse-fin:FourReportableSegmentRevenue03Member BIOCON2024-10-012024-12-31in-bse-fin:FourReportableSegmentRevenue04Member BIOCON2024-10-012024-12-31in-bse-fin:OneReportableSegmentResults01Member BIOCON2024-10-012024-12-31in-bse-fin:OneReportableSegmentResults02Member BIOCON2024-10-012024-12-31in-bse-fin:OneReportableSegmentResults03Member BIOCON2024-10-012024-12-31in-bse-fin:OneReportableSegmentResults04Member BIOCON2024-10-012024-12-31in-bse-fin:FourReportableSegmentResults01Member BIOCON2024-10-012024-12-31in-bse-fin:FourReportableSegmentResults02Member BIOCON2024-10-012024-12-31in-bse-fin:FourReportableSegmentResults03Member BIOCON2024-10-012024-12-31in-bse-fin:FourReportableSegmentResults04Member BIOCON2024-10-012024-12-31in-bse-fin:OneReportableSegmentAssets01Member BIOCON2024-10-012024-12-31in-bse-fin:OneReportableSegmentAssets02Member BIOCON2024-10-012024-12-31in-bse-fin:OneReportableSegmentAssets03Member BIOCON2024-10-012024-12-31in-bse-fin:OneReportableSegmentAssets04Member BIOCON2024-10-012024-12-31in-bse-fin:OneReportableSegmentLiabilities01Member BIOCON2024-12-31in-bse-fin:OneReportableSegmentLiabilities01Member BIOCON2024-10-012024-12-31in-bse-fin:OneReportableSegmentLiabilities02Member BIOCON2024-12-31in-bse-fin:OneReportableSegmentLiabilities02Member BIOCON2024-10-012024-12-31in-bse-fin:OneReportableSegmentLiabilities03Member BIOCON2024-12-31in-bse-fin:OneReportableSegmentLiabilities03Member BIOCON2024-10-012024-12-31in-bse-fin:OneReportableSegmentLiabilities04Member BIOCON2024-12-31in-bse-fin:OneReportableSegmentLiabilities04Member BIOCON2024-10-012024-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member BIOCON2024-10-012024-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member BIOCON2024-10-012024-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member BIOCON2024-10-012024-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532523 BIOCON NOTLISTED Biocon Limited Equity 2024-04-01 2025-03-31 2025-01-30 2025-01-03 INR Millions Third quarter 17:15:00 19:15:00 2025-01-30 2025-01-30 Not applicable Multi segment 2024-10-01 2024-12-31 Unaudited Consolidated 38214000000.00 348000000.00 38562000000.00 12930000000.00 855000000.00 -192000000.00 7883000000.00 2234000000.00 4254000000.00 9220000000.00 37184000000.00 1378000000.00 181000000.00 1559000000.00 1136000000.00 -388000000.00 748000000.00 0.00 811000000.00 0.00 0.00 0.00 0.00 811000000.00 566000000.00 1377000000.00 251000000.00 560000000.00 144000000.00 1233000000.00 6003000000.00 5 0.21 0.21 0.00 0.00 0.21 0.21 1. The unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024 in respect of Biocon Limited (‘the Company’) have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on January 30, 2025. The above results have been subjected to limited review by the statutory auditors of the Company. The reports of the statutory auditors are unqualified. 2. These financial results have been prepared in accordance with Indian Accounting Standards (‘Ind AS’) prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Due to size constraints, we are unable to provide full Notes in XBRL. Please refer Outcome of Board Meeting dated January 30, 2025 for full notes to the financial results for quarter ended 31.12.2024. Multi segment 2024-04-01 2024-12-31 Unaudited Consolidated 108447000000.00 11713000000.00 120160000000.00 31625000000.00 5431000000.00 190000000.00 23333000000.00 6850000000.00 12507000000.00 26987000000.00 106923000000.00 13237000000.00 761000000.00 13998000000.00 3632000000.00 666000000.00 4298000000.00 0.00 9700000000.00 0.00 0.00 0.00 0.00 9700000000.00 6205000000.00 15905000000.00 6688000000.00 3012000000.00 12172000000.00 3733000000.00 6003000000.00 5 5.59 5.58 0.00 0.00 5.59 5.58 Less: Recovery of cost from co-development partners (net) -341000000.00 Other Expenses 9561000000.00 Less: Recovery of cost from co-development partners (net) -1106000000.00 Other Expenses 28093000000.00 Biosimilars 22890000000.00 Generics 6864000000.00 Novel Biologics 0.00 Research Services 9437000000.00 Biosimilars 65540000000.00 Generics 19700000000.00 Novel Biologics 0.00 Research Services 26244000000.00 39191000000.00 111484000000.00 977000000.00 3037000000.00 38214000000.00 108447000000.00 Biosimilars 7000000.00 Generics -135000000.00 Novel Biologics 0.00 Research Services 1808000000.00 Biosimilars 10485000000.00 Generics -53000000.00 Novel Biologics 0.00 Research Services 3874000000.00 1680000000.00 14306000000.00 0.00 0.00 302000000.00 1. The unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024 in respect of Biocon Limited (‘the Company’) have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on January 30, 2025. The above results have been subjected to limited review by the statutory auditors of the Company. The reports of the statutory auditors are unqualified. 2. These financial results have been prepared in accordance with Indian Accounting Standards (‘Ind AS’) prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Due to size constraints, we are unable to provide full Notes in XBRL. Please refer Outcome of Board Meeting dated January 30, 2025 for full notes to the financial results for quarter ended 31.12.2024. 1069000000.00 1378000000.00 13237000000.00 Biosimilars 447148000000.00 Generics 78836000000.00 Novel Biologics 0.00 Research Services 60866000000.00 586850000000.00 -6708000000.00 580142000000.00 Biosimilars 247176000000.00 Generics 26872000000.00 Novel Biologics 0.00 Research Services 16045000000.00 290093000000.00 14393000000.00 304486000000.00 Items that will not be reclassified to profit or loss -3557000000.00 Items that will not be reclassified to profit or loss 1971000000.00 -3557000000.00 1971000000.00 134000000.00 120000000.00 Items that will be reclassified to profit or loss 3762000000.00 Items that will be reclassified to profit or loss 3983000000.00 3762000000.00 3983000000.00 -495000000.00 -371000000.00